30 April 2020
Visiongain has launched a new pharma report Global Neuromodulation Devices Report 2020-2030: Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Gastric Electrical Stimulation (GES), Other Applications.
Neuromodulation is one of the fastest growing sectors in the medical devices market for the potential it has as being a relatively non-invasive and cost-effective way of treating debilitating illnesses. This potential remains, yet, unexploited. Growing research into new forms of neuromodulation and the ways it can be applied to different illnesses will drive this market. This is because the techniques not only treat the symptoms of illnesses such as chronic pain, but also provides an effective alternative to drug-based medication that might cause severe side-effects or lead to drug dependence.
The lead analyst of the report commented "Ageing populations in both developed and developing countries and the increasing prevalence of age-related conditions and chronic diseases will drive growth in the neuromodulation devices market. Emerging economies such as China and India will see their neuromodulation devices market increase at a rapid rate during the second half of the forecasted period, due to increased development and research."
Leading companies featured in the report include Medtronic , Boston Scientific , Abbott Laboratories , LivaNova PLC , Stryker Corporation , Nevro Corp. & Other Companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.